Daiichi Sankyo 9-Month Profit Almost Triples After Settlement

Daiichi Sankyo Co. (4568), the worst performer on Japan’s Topix Pharmaceutical Index last year, said nine-month profit almost tripled from a year earlier, when net income was eroded by a provision to settle a legal dispute.

Profit was 51.5 billion yen ($567 million) for the nine months ended Dec. 31, from 17.5 billion yen a year earlier. Daiichi Sankyo still expects full-year profit of 50 billion yen, the Tokyo-based drugmaker said in a statement today.

Daiichi Sankyo, which owns 64 percent stake of India’s Ranbaxy Laboratories Ltd. (RBXY), accounts for the Indian unit’s earnings with a quarter lag. India’s biggest drugmaker is scheduled to report quarterly earnings on Feb. 26.

Daiichi Sankyo rose 0.8 percent to 1,546 yen as of 1:05 p.m. in Tokyo trading, while the benchmark Topix index declined 0.4 percent. The stock dropped 13 percent last year, while the 37- member Topix Pharmaceutical Index gained 12 percent.

To contact the reporter on this story: Kanoko Matsuyama in Tokyo at kmatsuyama2@bloomberg.net

To contact the editor responsible for this story: Jason Gale at j.gale@bloomberg.net

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.